Indian women with breast cancer had more than double the risk of cardiovascular disease mortality compared to Chinese women (HR 2.5), independent of age at diagnosis and tumor stage.
Cohort (n=5,868)
Yes
Indian ethnicity and older age are associated with a significantly higher risk of cardiovascular mortality in Southeast Asian women following breast cancer diagnosis, highlighting the need for targeted cardio-oncology risk stratification.
Hazard Ratio: 2.5 (95% CI 1.2–5.2)
Breast cancer incidence and survival is high in Southeast Asia. As such, many women diagnosed with breast cancer are at risk of dying of other causes. Given the increased risk of cardiotoxicity induced by breast cancer treatments, it is important to identify patients at high risk of cardiovascular disease (CVD) mortality. The aim of this study was to investigate if this risk varies by age and ethnicity. Patient details were obtained from 5,868 Chinese, Malay, and Indian women diagnosed with in situ or non-metastasized invasive breast cancer at the National University Hospital of Singapore and KK Women's and Children's Hospital in Singapore. Death causes were obtained from the National Registry of Births and Deaths. Flexible parametric survival models estimated CVD mortality rates and hazard ratios. During a median follow-up of six years, 1,010 deaths occurred of which 6.8% were due to CVD. CVD mortality rates of older women peaked within the first year following diagnosis and increased over time since diagnosis. Indian had more than double the risk of CVD mortality than Chinese, independent of age at diagnosis and stage. Taking ethnicity and age into account may promote CVD risk stratification and management in (Southeast Asian) women with breast cancer.
Gernaat et al. (Tue,) conducted a cohort in Breast cancer (n=5,868). Indian ethnicity vs. Chinese ethnicity was evaluated on Cardiovascular disease mortality within 10 years of diagnosis (HR 2.5, 95% CI 1.2-5.2). Indian women with breast cancer had more than double the risk of cardiovascular disease mortality compared to Chinese women (HR 2.5), independent of age at diagnosis and tumor stage.